The European Pharmacopoeia Commission adopted a chapter on chemical imaging for analytical development, quality control, and manufacturing.
The European Directorate for the Quality of Medicines & Healthcare (EDQM)
announcedon January 5, 2017 that the European Pharmacopoeia Commission had adopted chapter 5.24 Chemical Imaging in November 2016. The non-mandatory general chapter was created to further the use of chemical imaging in pharmaceutical formulation, analytical development, quality control, and manufacturing. The final text will be published in Supplement 9.3 in July 2017.
The new chapter addresses mid-infrared, near-infrared, and Raman spectroscopy and offers recommendations for the assessment of the performance of chemical imaging systems, including spectral and spatial components. The following elements are discussed in the chapter:
EDQM states that chemical imaging, which combines sensing technology with data analysis to characterize a sample area in chemical and physical terms, can be applied “to assess the identity, concentration and distribution of pharmaceutical ingredients in bulk or solid dosage forms, biological samples or packaging materials.” Users of chemical imaging can create “visual images of component distribution measured.”
Source:
EDQMA Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.